

A transition-metal-free azide-alkyne cycloaddition/oxetane ring opening cascade reaction for the construction of hydroxymethyl decorated triazole-fused piperazin-2-ones and [1,4]diazepin-4-one

Cong Fu^a, Mingjin Xu^a, Qicai Ma^a, Shanyue Li^a, Qingjie Zhao^{b,*}, Wei Zhou^{a,*}

^aState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510632, China.

E-mail: weizhou88@jnu.edu.cn

^bDepartment of Organic Chemistry, School of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
E-mail: qjzhao@smmu.edu.cn

Supporting Information


Table of Contents

I. General Remarks.....	S2
II. Synthesis of Substrates.....	S2
III. Procedure for Tandem Reactions.....	S11
IV. Synthetic Transformations.....	S22
V. X-Ray Crystallographic Data of 2a.....	S23
VI. NMR Spectra	S25

I. General Remarks

¹H NMR and ¹³C NMR spectra were recorded on a Bruker AV-400 or 500 MHz spectrometer. Chemical shifts (δ) are given in relative to tetramethylsilane (δ 0.00 ppm) in CDCl₃. Coupling constants, J , were reported in hertz unit (Hz). High resolution mass spectra (HRMS) were obtained on a Q-STAR Elite ESI-LC-MS/MS Spectrometer. Chemical names were generated using Cambridge Soft. ChemDraw Ultra 16.0. Commercially obtained reagents were used without further purification.

II. Synthesis of Substrates




A solution of **S1** (1.46 g, 10.0 mmol, 1.0 equiv.), DCC (2.5 g, 12.0 mmol, 1.2 equiv.), DMAP (0.122 g, 0.1 equiv.) in CH₂Cl₂ (20 mL) was stirred at 0 °C. Then **S2** (0.73 g, 10.0 mmol, 1.0 equiv.) was added dropwise to the solution. The reaction mixture was stirred at room temperature until full consumption of the starting material as monitored by thin layer chromatography. After completion, the reaction mixture was diluted with CH₂Cl₂ and washed 3 times with 0.5 M aq. HCl, dried over Na₂SO₄ and concentrated under reduced pressure. The obtained **S3** was used directly in the next step without further purification.

NaH (420 mg, 60% in mineral oil, 10.5 mmol, 1.5 equiv) was added to a solution of **S3** (1.4 g, 7.0 mmol, 1.0 equiv.) in THF (20.0 mL) at 0 °C in portions. The above solution was stirred for 20 mins at 0 °C then BnBr **S4** (1.43 g, 8.4 mmol, 1.2 equiv.) was added dropwise into the flask. The reaction mixture was allowed to stir at room temperature for another 6 h. After completion, the reaction was quenched with water and extract with ethyl acetate three times. The organic phase was dried over Na₂SO₄, and concentrated under reduced pressure. The crude residue was purified by a silica gel column chromatography to give the corresponding desired **1a** as white solid. (1.8 g, 84% yield)
¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.62-7.47 (m, 1H), 7.46-7.38 (m, 4H), 7.36-7.32 (m, 2H), 7.32-7.26 (m, 3H), 5.67&5.22 (2m, 1H), 5.08&5.00 (2s, 2H), 4.83& 4.75 (2q, J = 4.0 Hz, 4H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 155.4, 137.1, 136.7, 132.5, 130.5, 130.3, 129.1, 128.9, 128.7, 128.5, 128.0, 127.5, 126.7, 126.5, 120.0, 90.6, 81.6, 75.4, 52.8, 50.3, 49.9, 45.5. HRMS (ESI) calcd for C₁₉H₁₈NO₂⁺(M+H)⁺ 292.1332, found 292.1324.

The propiolamides **1b~1u** were prepared according to similar procedure of **1a**.


N-(cyclopropylmethyl)-N-(oxetan-3-yl)-3-phenylpropiolamide (**1b**)



The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.1 g, 63 %, yellow oil; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.55-7.50 (m, 2H), 7.43-7.33 (m, 3H), 5.57&5.12 (m, 1H), 4.93-4.77 (m, 4H), 3.63&3.54 (2d, J = 6.8 Hz, 2H), 1.09-0.97 (m, 1H), 0.62-


0.53 (m, 2H), 0.37-0.32 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3 , two rotamers) δ 154.8, 154.3, 132.4, 132.3, 130.3, 130.2, 128.6, 120.2, 120.1, 90.9, 89.9, 81.8, 81.5, 76.2, 75.4, 52.3, 51.2, 50.1, 46.5, 11.3, 10.7, 4.4, 4.1. HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{18}\text{NO}_2^+(\text{M}+\text{H})^+$ 256.1332, found 256.1325.

N-(cyclobutylmethyl)-*N*-(oxetan-3-yl)-3-phenylpropiolamide (**1c**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.0 g, 56%, yellow oil; ^1H NMR (400 MHz, CDCl_3 , two rotamers) δ 7.57-7.54 (m, 2H), 7.47-7.36 (m, 3H), 5.47&4.96 (m, 1H), 4.91&4.73 (m, 4H), 3.78&3.67 (2d, J =7.2 Hz, 2H), 2.63&2.46 (m, 1H), 2.13-2.02 (m, 2H), 1.96-1.74 (m, 4H). ^{13}C NMR (100 MHz, CDCl_3 , two rotamers) δ 154.9, 154.4, 132.4, 132.4, 130.3, 130.2, 128.6, 120.3, 120.2, 90.9, 90.1, 81.5, 81.9, 76.2, 75.4, 52.3, 51.9, 50.3, 47.6, 35.7, 35.2, 26.9, 26.2, 18.3, 18.2. HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{20}\text{NO}_2^+(\text{M}+\text{H})^+$ 270.1489, found 270.1482.

N-(cyclopentylmethyl)-*N*-(oxetan-3-yl)-3-phenylpropiolamide (**1d**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.1 g, 60%, yellow oil; ^1H NMR (400 MHz, CDCl_3 , two rotamers) δ 7.54-7.49 (m, 2H), 7.43-7.32 (m, 3H), 5.42& 4.90 (m, 1H), 4.88-4.75 (m, 4H), 3.64&3.56 (2d, J =7.6 Hz, 2H), 2.16&1.97 (m, 1H), 1.76-1.68 (m, 2H), 1.66-1.60 (m, 2H), 1.58-1.51(m, 2H), 1.30-1.20 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3 , two rotamers) δ 154.8, 154.4, 132.3, 132.3, 130.3, 130.2, 128.6, 120.3, 120.2, 90.8, 90.0, 81.9, 81.7, 76.1, 75.2, 52.2, 51.6, 50.5, 47.1, 39.9, 39.6, 30.5, 30.1, 24.8, 24.8. HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{22}\text{NO}_2^+(\text{M}+\text{H})^+$ 284.1645, found 284.1637.

N-allyl-*N*-(oxetan-3-yl)-3-phenylpropiolamide (**1e**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.4 g, 85%, white solid; ^1H NMR (400 MHz, CDCl_3 , two rotamers) δ 7.59-7.53 (m, 2H), 7.49-7.36 (m, 3H), 6.01-5.90 (m, 1H), 5.69&5.36 (m, 1H), 5.31-5.18 (m, 2H), 4.94-4.76 (m, 4H), 4.47&4.37 (2dt, J =5.2, 1.6 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3 , two rotamers) δ 155.1, 153.9, 133.8, 133.2, 132.5, 132.4, 132.3, 130.4, 130.3, 129.9, 128.7, 128.6, 128.5, 120.6, 120.2, 120.0, 117.5, 116.6, 91.2, 90.1, 81.6, 81.1, 76.0, 75.5, 52.8, 49.5, 48.5, 44.4, 38.4, 34.1. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_2^+(\text{M}+\text{H})^+$ 242.1176, found 242.1168.

N-(oxetan-3-yl)-*N*-(pent-4-en-1-yl)-3-phenylpropiolamide (**1f**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.3 g, 72 %, colorless oil, ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.57-7.53 (m, 2H), 7.47-7.36 (m, 3H), 5.86-5.76 (m, 1H), 5.62&5.17 (m, 1H), 5.11&5.07 (2q, *J* = 1.6 Hz, 1H), 5.04&5.02 (m, 1H), 4.94-4.74 (m, 4H), 3.76&3.65 (m, 2H), 2.18-2.13 (m, 2H), 1.80-1.72 (m, 2H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 154.8, 154.0, 137.3, 136.9, 132.4, 132.4, 130.3, 128.6, 120.3, 120.1, 116.0, 115.5, 90.8, 89.9, 81.7, 81.3, 76.1, 75.5, 52.6, 49.7, 46.1, 42.2, 31.2, 30.9, 29.4, 27.9. HRMS (ESI) calcd for C₁₇H₂₀NO₂⁺(M+H)⁺ 270.1489, found 270.1479.

N-(oxetan-3-yl)-*N*-phenethyl-3-phenylpropiolamide (**1g**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.4 g, 66 %, white solid, ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.60-7.55 (m, 2H), 7.50-7.39 (m, 3H), 7.37-7.21 (m, 5H), 5.54&5.15 (m, 1H), 4.80&4.64 (m, 4H), 4.00&2.88 (2t, *J* = 7.6 Hz, 2H), 3.02-2.98(m, 2H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 154.9, 138.7, 137.7, 132.5, 132.5, 130.4, 130.4, 128.9, 128.9, 128.8, 128.8, 128.7, 127.0, 126.8, 120.2, 120.1, 90.9, 90.0, 81.7, 81.3, 76.1, 75.5, 52.8, 50.0, 48.2, 44.7, 37.1, 34.6, 29.7. HRMS (ESI) calcd for C₂₀H₂₀NO₂⁺(M+H)⁺ 306.1489, found 306.1479.

N-(2-(benzyloxy)ethyl)-*N*-(oxetan-3-yl)-3-phenylpropiolamide (**1h**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 0.98 g, 42 %, yellow solid, ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.59-7.51 (m, 2H), 7.48-7.42 (m, 2H), 7.38-7.30 (m, 6H), 5.58&5.15 (m, 1H), 4.94&4.87 (2t, *J* = 8.0 Hz, 2H), 4.79&4.53 (2d, *J* = 7.6Hz, 4H), 3.97&3.89 (2t, *J* = 5.6 Hz, 2H), 3.74&3.70 (2t, *J* = 5.2Hz, 2H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 154.9, 154.3, 137.9, 137.6, 132.5, 130.4, 130.3, 128.6, 128.6, 128.5, 128.5, 120.2, 120.1, 90.9, 90.2, 81.7, 81.4, 76.4, 75.6, 73.5, 73.4, 71.5, 69.3, 67.8, 61.9, 53.0, 50.7, 46.4, 42.9. HRMS (ESI) calcd for C₂₁H₂₂NO₃⁺(M+H)⁺ 336.1594, found 336.1585.

N-benzyl-3-(2-bromophenyl)-*N*-(oxetan-3-yl)propiolamide (**1i**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 2.2 g, 88 %, white solid; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.68-7.55 (m, 2H), 7.40-7.26 (m, 7H), 5.99&5.18 (m, 1H), 5.17&5.05 (2s, 2H), 4.89-4.70 (m, 4H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 154.9, 137.3, 136.6, 134.9, 134.9, 132.8, 132.6, 131.7, 131.5, 129.0, 128.9, 127.9, 127.5, 127.3, 126.7, 126.2, 122.6, 88.2, 85.3, 75.8, 75.4, 53.0, 50.4, 49.9, 45.2. HRMS (ESI) calcd for C₁₉H₁₈BrNO₂⁺(M+H)⁺ 370.0437, found 370.0426.

N-benzyl-*N*-(oxetan-3-yl)-3-(o-tolyl)propiolamide (**1j**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.9 g, 92 %, white solid; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.56-7.33 (m, 3H), 7.32-7.23 (m, 4H), 7.21-7.11 (m, 2H), 5.74&5.23(m, 1H), 5.09&5.00 (2s, 2H), 4.80&4.73 (2d, J =7.2 Hz, 4H), 2.52&2.27 (2s, 3H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 155.6, 154.8, 141.6, 137.3, 136.7, 133.1, 133.0, 130.5, 130.3, 129.9, 129.7, 129.1, 128.9, 127.9, 127.5, 126.7, 126.4, 126.0, 125.8, 119.9, 89.6, 85.3, 75.8, 75.4, 52.9, 50.2, 49.8, 45.4, 20.8, 20.5. HRMS (ESI) calcd for C₂₀H₂₀NO₂⁺(M+H)⁺ 306.1489, found 306.1479.

N-benzyl-*N*-(oxetan-3-yl)-3-(m-tolyl)propiolamide (**1k**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.9 g, 91 %, white solid; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.42-7.38 (m, 2H), 7.36-7.33 (m, 1H), 7.33-7.25 (m, 4H), 7.23-7.21 (m, 2H), 5.66&5.20 (m, 1H), 5.08&4.99 (2s, 2H), 4.84&4.71 (m, 4H), 2.39&2.32 (2s, 3H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 155.4, 154.7, 138.5, 138.4, 137.2, 136.7, 133.0, 132.9, 131.5, 131.3, 129.6, 129.1, 128.8, 128.6, 128.4, 127.9, 127.5, 126.7, 126.6, 119.8, 92.1, 90.9, 81.3, 80.86, 75.8, 75.4, 52.7, 50.3, 49.8, 45.5, 21.1. HRMS (ESI) calcd for C₂₀H₂₀NO₂⁺(M+H)⁺ 306.1489, found 306.1479.

N-benzyl-*N*-(oxetan-3-yl)-3-(p-tolyl)propiolamide (**1l**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.8 g, 87 %, white solid; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.49-7.36 (m, 2H), 7.33-7.24 (m, 5H), 7.21&7.12 (2d, *J* = 8.0 Hz, 2H), 5.64&5.20 (m, 1H), 5.05&4.97(2s, 2H), 4.81&4.72 (2d, *J* = 7.2 Hz, 4H), 2.40&2.35 (2s, 3H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 155.5, 140.9, 136.8, 132.5, 129.5, 129.3, 129.1, 128.9, 127.9, 127.5, 126.7, 126.6, 116.9, 75.9, 75.4, 52.7, 50.3, 49.8, 45.5, 21.6. HRMS (ESI) calcd for C₂₀H₂₀NO₂⁺(M+H)⁺ 306.1489, found 306.1479.

N-benzyl-3-(4-methoxyphenyl)-N-(oxetan-3-yl)propiolamide (**1m**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 2.1g, 95 %, white solid ; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.56-7.33 (m, 4H), 7.33-7.24 (m, 3H), 6.94-6.79 (m, 2H), 5.64&5.20 (m, 1H), 5.06&4.97 (2s, 2H), 4.82-4.69 (m, 4H), 3.84&3.80 (2s, 3H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 161.2, 154.9, 155.7, 137.3, 136.9, 134.4, 129.1, 128.8, 127.9, 127.4, 126.7, 126.6, 114.4, 114.2, 111.8, 92.4, 91.2, 81.1, 80.7, 75.9, 75.4, 55.4, 55.4, 52.7, 50.2, 49.8, 45.4. HRMS (ESI) calcd for C₂₀H₂₀NO₃⁺(M+H)⁺ 322.1438, found 322.1428.

N-benzyl-3-(4-fluorophenyl)-N-(oxetan-3-yl)propiolamide (**1n**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.7 g, 82 %, white solid; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.62-7.19 (m, 7H), 7.11-6.90 (m, 2H), 5.60&5.16 (m, 1H), 5.02&4.94 (2s, 2H), 4.79-4.67 (m, 4H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 164.9, 163.7&163.6 (2d, *J* = 252.0 Hz), 162.3, 155.1, 154.4, 137.2, 136.8, 134.8&134.7(2d, *J* = 8.0 Hz), 129.0, 128.8, 127.9, 127.4, 126.7, 126.5, 116.2&116.0 (2d, *J* = 22.0 Hz), 115.9, 90.5, 89.4, 81.6&81.1 (2d,*J* = 1.0 Hz), 75.7, 75.2, 52.7, 50.2, 49.9, 45.5. HRMS (ESI) calcd for C₁₉H₁₇FNO₂⁺(M+H)⁺ 310.1238, found 310.1230.

N-benzyl-3-(4-chlorophenyl)-N-(oxetan-3-yl)propiolamide (**1o**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 2.2g, 87 %, white solid; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.55-7.37 (m, 3H), 7.36-7.25 (m, 6H), 5.63&5.21 (m, 1H), 5.06&4.99 (2s, 2H), 4.85&4.71 (m 4H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 155.1, 154.3, 137.0, 136.9, 136.7, 136.7, 133.7, 129.2, 129.1, 129.0, 128.9, 128.0, 127.6, 126.7, 126.5, 118.5, 90.5, 89.3, 82.4, 82.0, 75.8, 75.3, 52.8, 50.3, 49.9, 45.6. HRMS (ESI) calcd for C₁₉H₁₇ClNO₂⁺(M+H)⁺ 326.0942, found 326.0934.

N-benzyl-3-(4-bromophenyl)-*N*-(oxetan-3-yl)propiolamide (**1p**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 2.2g, 86 %, white solid; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.58-7.38 (m, 4H), 7.36-7.26 (m, 5H), 5.63&5.22 (m, 1H), 5.06&4.98 (2d, J = 7.2 Hz, 2H), 4.83-4.72 (m, 4H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 155.1, 154.3, 137.0, 136.6, 133.8, 132.1, 131.9, 129.1, 128.9, 128.0, 127.6, 126.8, 126.5, 125.2, 125.1, 118.9, 90.6, 89.4, 82.6, 82.1, 75.8, 75.3, 52.8, 50.3, 49.9, 45.6. HRMS (ESI) calcd for C₁₉H₁₇BrNO₂⁺(M+H)⁺ 370.0437, found 370.0430.

N-benzyl-*N*-(oxetan-3-yl)-3-(4-(trifluoromethyl)phenyl)propiolamide (**1q**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 2.2g, 90 %, white solid; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.73-7.68 (m, 1H), 7.62&7.51 (m, 3H), 7.45-7.31 (m, 3H), 7.31-7.24 (m, 2H), 5.64&5.24 (m, 1H), 5.07-5.01 (2s, 2H), 4.86-4.74 (m, 4H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 154.79, 154.04, 136.93, 136.52, 131.9 (q, J = 33.0 Hz), 128.06, 127.62, 126.75, 126.42, 125.7&125.5 (2q, J = 3.0 Hz), 124.89, 123.82, 122.18, 89.72, 88.50, 83.30, 82.80, 75.27, 52.83, 50.26, 49.94, 45.63. HRMS (ESI) calcd for C₂₀H₁₇F₃NO₂⁺(M+H)⁺ 360.1206, found 360.1197.

N-benzyl-3-(3,5-dichlorophenyl)-*N*-(oxetan-3-yl)propiolamide (**1r**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 2.2 g, 89%, white solid; ^1H NMR (400 MHz, CDCl_3 , two rotamers) δ 7.46 (s, 1H), 7.43-7.39 (m, 2H), 7.38-7.27 (m, 3H), 7.26-7.25 (m, 2H), 5.60&5.22 (m, 1H), 5.04&4.99 (2s, 2H), 4.82&4.74 (2d, J = 7.2 Hz, 4H). ^{13}C NMR (100 MHz, CDCl_3 , two rotamers) δ 154.5, 153.7, 137.0, 136.5, 135.4, 135.2, 130.7, 130.6, 130.4, 129.2, 128.9, 128.1, 127.6, 126.7, 126.4, 122.8, 88.2, 87.0, 83.3, 82.8, 75.6, 75.2, 52.8, 50.2, 50.0, 45.6. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{16}\text{Cl}_2\text{NO}_2^+(\text{M}+\text{H})^+$ 360.0553, found 360.0544.

N-benzyl-*N*-(oxetan-3-yl)-3-(thiophen-2-yl)propiolamide (**1s**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.5 g, 76 %, yellow solid; ^1H NMR (400 MHz, CDCl_3 , two rotamers) δ 7.49-7.37 (m, 3H), 7.36-7.30 (m, 2H), 7.29-7.25 (m, 2H), 7.11-7.01 (m, 1H), 5.59&5.21 (m, 1H), 5.04&4.99 (2s, 2H), 4.77-4.71 (m, 4H). ^{13}C NMR (100 MHz, CDCl_3 , two rotamers) δ 155.2, 137.1, 136.7, 135.7, 135.6, 130.7, 130.6, 129.1, 128.9, 128.0, 127.6, 127.5, 127.5, 126.8, 126.6, 119.7, 85.8, 75.8, 75.3, 52.6, 50.2, 49.9, 45.5. HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{16}\text{NO}_2\text{S}^+(\text{M}+\text{H})^+$ 298.0896, found 298.0887.

N-benzyl-*N*-(oxetan-3-yl)but-2-ynamide (**1t**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.3 g, 83 %, colorless oil; ^1H NMR (400 MHz, CDCl_3 , two rotamers) δ 7.41-7.30 (m, 2H), 7.36-7.23 (m, 1H), 7.22-7.17 (m, 2H), 5.60&5.08 (m, 1H), 4.96&4.92 (2s, 2H), 4.75-4.62 (m, 4H), 2.05&1.95 (2s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , two rotamers) δ 155.4, 137.3, 136.8, 129.0, 128.8, 127.9, 127.4, 126.6, 126.5, 89.6, 75.8, 75.3, 73.4, 52.7, 50.3, 49.7, 45.1, 4.1. HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{16}\text{NO}_2^+(\text{M}+\text{H})^+$, 230.1176, found 230.1170.

N-benzyl-*N*-(oxetan-3-yl)oct-2-ynamide (**1u**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.5 g, 79%, colorless oil; ^1H NMR (400 MHz, CDCl_3 , two rotamers) δ 7.40–7.25 (m, 3H), 7.23–7.20 (m, 2H), 5.60&5.14 (m, 1H), 4.98&4.93 (2s, 2H), 4.76&4.65 (m, 4H), 2.40&2.29 (2t, J = 7.2 Hz, 2H), 1.67&1.44 (m, 2H), 1.44–1.34 (m, 1H), 1.30–1.21 (m, 3H), 0.93&0.83 (2t, J = 8.0 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3 , two rotamers) δ 155.5, 137.4, 136.9, 129.0, 128.8, 127.8, 127.4, 126.7, 126.4, 95.0, 95.2, 93.8, 75.8, 75.4, 52.7, 50.2, 49.7, 45.2, 31.1, 30.9, 27.4, 27.3, 22.1, 22.0, 19.0, 18.8, 13.9, 13.8. HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{24}\text{NO}_2^+(\text{M}+\text{H})^+$ 286.1802, found 286.1793.

Synthesis of substrate **1v**




Cs_2CO_3 (780 mg, 2.4 mmol, 1.2 equiv) was added to a solution of *N*-(prop-2-yn-1-yl)oxetan-3-amine (222 mg, 2.0 mmol, 1.0 equiv.) in CH_3CN (20.0 mL). Then BnBr **S4** (424 mg, 2.4 mmol, 1.2 equiv.) was added dropwise into the flask. The reaction mixture was allowed to stir at 70 °C for another 3 h. After completion, the reaction was quenched with water and extract with ethyl acetate three times. The organic phase was dried over Na_2SO_4 , and concentrated under reduced pressure. The crude residue was purified by a silica gel column chromatography (ethyl acetate/petroleum ether = 1:5) to give the corresponding desired **1v** as yellow oil (381 mg, 95% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.40 – 7.30 (m, 5H), 4.71 – 4.64 (m, 4H), 4.09 (m, J = 6.7 Hz, 1H), 3.59 (s, 2H), 3.23 (d, J = 2.4 Hz, 2H), 2.25 (t, J = 2.4 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 129.2, 128.4, 127.5, 127.0, 76.1, 73.5, 56.2, 53.6, 38.6. HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{16}\text{NO}^+(\text{M}+\text{H})^+$ 202.1226, found 202.1219.

N-benzyl-*N*-(oxetan-3-ylmethyl)-3-phenylpropiolamide (**3a**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.9g, 93%, white solid; ^1H NMR (400 MHz, CDCl_3 , two rotamers) δ 7.62–7.48 (m, 2H), 7.47–7.37 (m, 3H), 7.37–7.23 (m, 5H), 4.87&4.66 (2s, 2H), 4.70&4.64 (2t, 2H), 4.46&4.38 (2t, J = 6.4 Hz, 2H), 4.00&3.71 (2d, J = 7.2 Hz, 2H), 3.35–3.21 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3 , two rotamers) δ 155.3, 155.1, 136.4, 136.3, 132.5, 132.5, 130.4, 130.3, 129.0, 128.8, 128.7, 128.6, 128.2, 127.8, 127.3, 120.2, 91.5, 90.9, 81.5, 75.6, 74.9, 53.8, 51.4, 48.0, 47.7, 34.4, 34.1. HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{20}\text{NO}_2^+(\text{M}+\text{H})^+$ 306.1489, found 306.1481.

N-benzyl-3-(4-fluorophenyl)-*N*-(oxetan-3-ylmethyl)propiolamide (**3b**)




The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 2.2g, 97%, white solid; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.62-7.43 (m, 2H), 7.43-7.32 (m, 3H), 7.31-7.22 (m, 2H), 7.21-7.02 (m, 2H), 4.85&4.65 (2s, 2H), 4.70&4.65 (2t, *J* = 6.4 Hz, 2H), 4.45& 4.37 (2t, *J* = 6.4 Hz, 2H), 4.00&3.72 (2d, *J* = 7.2 Hz, 2H), 3.32-3.23 (m, 1H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 163.7&163.6 (2d, *J* = 251.0 Hz), 155.2, 155.0, 136.3, 136.2, 134.7&134.6 (2d, *J* = 9.0 Hz), 129.1, 128.8, 128.2, 127.8, 127.3, 116.3, 116.2, 116.1, 115.9, 90.5, 89.8, 75.6, 74.8, 53.8, 51.3, 48.0, 47.8, 34.3, 34.0. HRMS (ESI) calcd for C₂₀H₁₉FNO₂⁺(M+H)⁺ 324.1394, found 324.1385.

N-benzyl-3-(4-chlorophenyl)-*N*-(oxetan-3-ylmethyl)propiolamide (**3c**)



The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 2.2g, 93%, white solid; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.56-7.41 (m, 2H), 7.41-7.33 (m, 4H), 7.33-7.22 (m, 3H), 4.85&4.66 (2s, 2H), 4.70&4.64 (2t, *J* = 6.8Hz, 2H), 4.44&4.37 (2t, *J* = 6.4Hz, 2H), 3.99&3.72 (2d, *J* = 7.2 Hz, 2H), 3.32-3.22 (m, 1H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 155.1, 154.8, 136.6, 136.3, 136.1, 133.7, 133.7, 129.1, 129.1, 129.0, 128.9, 128.2, 127.8, 127.3, 118.7, 90.3, 89.6, 82.3, 75.4, 74.8, 53.8, 51.3, 47.8, 34.3, 34.0. HRMS (ESI) calcd for C₂₀H₁₉ClNO₂⁺(M+H)⁺ 340.1099, found 340.1090.


N-benzyl-3-(4-bromophenyl)-*N*-(oxetan-3-ylmethyl)propiolamide(**3d**)



The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 2.3g, 91% ,white solid; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.56-7.45 (m, 3H), 7.43-7.32 (m, 4H), 7.31-7.23 (m, 2H), 4.85&4.65 (2s, 2H), 4.70&4.64 (2q, *J* = 6.4 Hz, 2H), 4.44&4.37 (2t, *J* = 6.0 Hz, 2H), 3.99 &3.72 (2d, *J* = 7.2 Hz, 2H), 3.30-3.28 (m, 1H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 155.0, 154.8, 136.1, 133.8, 133.8, 132.1, 131.9, 129.1, 128.9, 128.2, 127.9, 127.8, 127.3, 124.9, 119.1, 90.4, 89.6, 82.4, 75.6, 74.8, 53.8, 51.3, 48.0, 47.8, 34.3, 34.0. HRMS (ESI) calcd


for $C_{20}H_{19}BrNO_2^+(M+H)^+$ 384.0594, found 384.0581.

N-benzyl-*N*-(oxetan-3-ylmethyl)-3-(p-tolyl)propiolamide(**3e**)



The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.9g, 88%, colorless oil; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.53-7.39 (m, 2H), 7.39-7.29 (m, 4H), 7.29-7.23 (m, 1H), 7.22-7.15 (m, 2H), 4.87&4.66 (2s, 2H), 4.70&4.64 (2q, *J* = 6.0 Hz, 2H), 4.47&4.38 (2t, *J* = 6.0 Hz, 2H), 4.00&3.72 (2d, *J* = 7.6 Hz, 2H), 3.35-3.24 (m, 1H), 2.41&2.38 (2s, 3H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 155.5, 155.2, 141.0, 140.8, 136.5, 136.4, 132.5, 132.4, 129.5, 129.3, 129.0, 128.8, 128.1, 127.8, 127.4, 117.1, 92.0, 91.3, 81.1, 75.6, 74.9, 53.8, 51.3, 48.0, 47.7, 34.4, 34.1, 21.7, 21.0. HRMS (ESI) calcd for C₂₁H₂₂NO₂^{+(M+H)} 320.1645, found 320.1636.


N-benzyl-3-(3,5-dimethylphenyl)-*N*-(oxetan-3-ylmethyl)propiolamide (**3f**)



The product was purified by silica gel column chromatography (ethyl acetate/petroleum ether = 1:5). 1.9g, 83%, colorless oil; ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.43-7.35 (m, 2H), 7.35-7.31 (m, 2H), 7.30-7.20 (m, 2H), 7.13-7.03 (m, 2H), 4.87&4.66 (2s, 2H), 4.69 &4.64 (2q, *J* = 6.4 Hz, 1H), 4.47&4.38 (2t, *J* = 6.0 Hz, 2H), 3.99 &3.71 (2d, *J* = 7.2 Hz, 2H), 3.33-3.26 (m, 2H), 2.33&2.29 (2s, 6H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 155.4, 155.2, 138.3, 138.2, 136.5, 136.4, 132.3, 132.2, 130.1, 129.0, 128.8, 128.1, 127.8, 127.4, 119.8, 92.1, 91.4, 81.0, 75.6, 75.0, 53.8, 51.3, 48.0, 47.7, 34.4, 34.1, 21.1, 21.0. HRMS (ESI) calcd for C₂₂H₂₄NO₂^{+(M+H)} 334.1802, found 334.1792.

III. Procedure for the tandem azide-alkyne cycloaddition/oxetane ring opening cascade reaction


General procedure for the Synthesis of [1,2,3]triazolo[1,5-a]pyrazin-4(5H)-ones.



A mixture of **1** (0.2 mmol, 1.0 equiv), NaN₃ (0.2 mmol, 12.6 mg, 1.0 equiv), NaHCO₃ (0.2 mmol, 16.8 mg, 1.0 equiv) in DMSO (2 mL) was stirred at 80 °C for 12 hours. After the reaction was completed (monitored by TLC), H₂O (15.0 mL) and ethyl acetate (50.0 mL) were added. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (10.0 mL × 3). The combined organic


phase was washed with H₂O (10.0 mL × 5) and brine, dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue was purified by flash chromatography (dichloromethane/methanol = 100/1) to afford the desired products **2**.

5-benzyl-6-(hydroxymethyl)-3-phenyl-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2a**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 62.4 mg, 93%, white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.28-8.14 (m, 2H), 7.44 (m, 3H), 7.39-7.29 (m, 5H), 5.43 (d, *J* = 14.8 Hz, 1H), 4.90 (d, *J* = 13.6 Hz, 1H), 4.65 (s, 1H), 4.23 (dd, *J* = 13.6, 4.8 Hz, 1H), 4.14 (d, *J* = 14.8 Hz, 1H), 3.84-3.80 (m, 1H), 3.68 (dd, *J* = 11.6, 4.4 Hz, 1H), 3.57 (t, *J* = 9.2 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 156.3, 148.4, 136.5, 129.5, 129.1, 128.9, 128.8, 128.5, 128.3, 128.3, 123.9, 59.1, 56.0, 48.6, 45.7. HRMS (ESI) calcd for C₁₉H₁₉N₄O₂⁺(M+H)⁺ 335.1503, found 335.1493

5-(cyclopropylmethyl)-6-(hydroxymethyl)-3-phenyl-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2b**)



The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 49.3 mg, 83%, white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.23-8.11 (m, 2H), 7.51-7.35 (m, 3H), 5.03 (d, *J* = 13.6 Hz, 1H), 4.45 (dd, *J* = 13.6, 4.8 Hz, 1H), 4.04-3.99 (m, 1H), 3.86-3.77 (m, 2H), 3.56 (t, *J* = 10.4 Hz, 1H), 3.37 (s, 1H), 3.14-3.11 (dd, *J* = 14.4, 6.8 Hz, 1H), 1.12-1.06 (m, 1H), 0.64-0.54 (m, 2H), 0.39-0.30 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 156.1, 148.1, 129.5, 128.9, 128.7, 128.5, 124.1, 59.2, 56.9, 50.1, 45.6, 10.1, 4.2, 3.6. HRMS (ESI) calcd for C₁₆H₁₉N₄O₂⁺(M+H)⁺ 299.1503, found 299.1493.


5-(cyclobutylmethyl)-6-(hydroxymethyl)-3-phenyl-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2c**)



The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 52.1 mg, 84%, white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, *J* = 12.0 Hz, 2H), 7.48-7.39 (m, 3H), 5.19 (s, 1H), 4.98 (d, *J* = 13.6 Hz, 1H), 4.36 (d, *J* = 13.6 Hz, 1H), 4.18-4.13 (m, 1H), 3.84-3.79 (m, 1H),


3.69 (d, $J = 12.0$ Hz, 1H), 3.51 (t, $J = 11.6$ Hz, 1H), 3.11-3.05 (m, 1H), 2.72-2.64(m, 2H), 1.96-1.87 (m, 3H), 1.83-1.75 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 156.2, 148.1, 129.4, 128.7, 128.4, 124.1, 59.0, 57.3, 50.8, 45.4, 34.3, 26.3, 26.1, 18.4. HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{21}\text{N}_4\text{O}_2^+(\text{M}+\text{H})^+$ 313.1659, found 313.1649.

5-(cyclopentylmethyl)-6-(hydroxymethyl)-3-phenyl-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2d**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 55.1 mg, 84%, white solid; ^1H NMR (400 MHz, CDCl_3) δ 8.27-8.16 (m, 2H), 7.50-7.42 (m, 3H), 5.05 (d, $J = 13.6$ Hz, 1H), 4.46-4.44(dd, $J = 13.6, 8.8$ Hz, 1H), 4.22-4.19 (dd, $J = 13.6, 8.0$ Hz, 1H), 3.95-3.90(m, 1H), 3.77 (dd, $J = 11.6, 4.8$ Hz, 1H), 3.58 (m, 1H), 2.93-2.90 (dd, $J = 13.6, 7.6$ Hz ,1H), 2.36-2.28 (m, 1H), 1.83-1.74 (m, 2H), 1.73-1.68(m, 2H), 1.65-1.56 (m, 2H), 1.32-1.27 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 156.3, 148.2, 129.4, 129.0, 128.7, 128.4, 124.1, 59.1, 57.2, 50.4, 45.4, 39.0, 30.6, 30.2, 25.1, 24.8. HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{23}\text{N}_4\text{O}_2^+(\text{M}+\text{H})^+$ 327.1816, found 327.1807.

5-allyl-6-(hydroxymethyl)-3-phenyl-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2e**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 46.7 mg, 82%, white solid; ^1H NMR (400 MHz, CDCl_3) δ 8.27-8.19 (m, 2H), 7.54-7.39 (m, 3H), 5.93-5.83 (m, 1H), 5.34 (d, $J = 11.6$ Hz, 1H), 5.31 (d, $J = 4.4$ Hz, 1H), 5.05 (d, $J = 13.6$ Hz, 1H), 4.74 (dd, $J = 15.2, 4.8$ Hz, 1H), 4.44 (dd, $J = 13.6, 4.8$ Hz, 1H), 4.36 (t, $J = 5.6$ Hz, 1H), 3.94-3.89 (m, 1H), 3.80-3.72 (m, 2H), 3.63-3.60 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 155.9, 148.4, 132.3, 129.5, 128.9, 128.7, 128.5, 123.9, 119.1, 59.3, 56.2, 48.1, 45.6. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{17}\text{N}_4\text{O}_2^+(\text{M}+\text{H})^+$ 285.1346, found 285.1338.

6-(hydroxymethyl)-5-(pent-4-en-1-yl)-3-phenyl-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2f**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 59.4 mg, 95%; ¹H NMR (400 MHz, CDCl₃) δ 8.22-8.14 (m, 2H), 7.51-7.39 (m, 3H), 5.87-5.77 (m, 1H), 5.10-4.99 (m, 3H), 4.43-4.39 (dd, *J* = 13.6, 4.8 Hz, 1H), 4.10-4.07 (m, 1H), 3.87-3.83 (m, 1H), 3.75-3.71 (dd, *J* = 11.6, 4.4 Hz, 1H), 3.57 (t, *J* = 10.0 Hz, 1H), 3.10-3.03 (m, 1H), 2.17-2.11 (m, 2H), 1.82-1.74 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 156.0, 148.1, 137.2, 129.5, 128.9, 128.7, 128.5, 124.1, 115.7, 59.2, 57.4, 46.0, 45.5, 31.0, 27.5. HRMS (ESI) calcd for C₁₇H₂₁N₄O₂⁺(M+H)⁺ 313.1659 found 313.1649.

6-(hydroxymethyl)-5-phenethyl-3-phenyl-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2g**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 64.1 mg, 93%, white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.15 (d, *J* = 7.6 Hz, 2H), 7.52-7.36 (m, 3H), 7.35-7.27 (m, 2H), 7.29-7.22 (m, 1H), 7.21 (d, *J* = 7.6 Hz, 2H), 4.70 (d, *J* = 16.4 Hz, 1H), 4.45-4.39 (m, 1H), 3.92-3.89 (dt, *J* = 4.0 Hz, 1H), 3.62-3.59 (d, *J* = 13.6, 4.0 Hz, 1H), 3.48-3.42 (m, 1H), 3.37-3.34 (m, 1H), 3.21-3.13 (m, 1H), 3.05-2.93 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 156.0, 148.1, 138.3, 129.5, 129.0, 128.9, 128.7, 128.5, 127.0, 124.0, 59.2, 58.5, 49.0, 45.1, 34.3. HRMS (ESI) calcd for C₂₀H₂₁N₄O₂⁺(M+H)⁺ 349.1659, found 349.1647.

5-(2-(benzyloxy)ethyl)-6-(hydroxymethyl)-3-phenyl-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2h**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 71.6 mg, 96%, white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.21-8.18 (m, 2H), 7.49-7.39 (m, 3H), 7.37-7.28 (m, 5H), 4.89 (dd, *J* = 13.6, 1.6 Hz, 1H), 4.66 (t, *J* = 6.0 Hz, 1H), 4.52 (s, 2H), 4.36 (dd, *J* = 13.6, 4.8 Hz, 1H), 4.21 (dt, *J* = 14.4, 4.0 Hz, 1H), 4.10-4.04 (m, 1H), 3.76-3.73 (m, 2H), 3.72-3.69 (m, 1H), 3.56-3.50 (m, 1H), 3.42-3.36 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 156.4, 148.1, 137.6, 129.4, 129.1, 128.7, 128.6, 128.4, 128.0, 127.8, 124.0, 73.5, 68.7, 59.7, 58.7, 46.7, 45.6. HRMS (ESI) calcd for C₂₁H₂₃N₄O₃⁺(M+H)⁺ 379.1765, found 379.1755.

5-benzyl-3-(2-bromophenyl)-6-(hydroxymethyl)-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2i**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 75.2 mg, 91%, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, *J* = 7.6 Hz, 1H), 7.52 (d, *J* = 7.6 Hz, 1H), 7.41 (t, *J* = 7.6 Hz, 1H), 7.31 (s, 6H), 5.30 (d, *J* = 14.4 Hz, 1H), 4.92 (d, *J* = 13.6 Hz, 1H), 4.25 (d, *J* = 13.6 Hz, 1H), 4.12 (d, *J* = 14.4 Hz, 1H), 3.79 (s, 1H), 3.63 (d, *J* = 7.2 Hz, 2H), 3.28 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 155.7, 147.0, 136.4, 133.0, 131.9, 130.9, 130.4, 129.1, 128.3, 128.3, 127.4, 125.9, 123.8, 58.9, 56.3, 48.3, 45.5. HRMS (ESI) calcd for C₁₉H₁₈BrN₄O₂⁺(M+H)⁺ 413.0608, found 413.0595.

5-benzyl-6-(hydroxymethyl)-3-(o-tolyl)-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2j**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 65.1 mg, 94%, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.43 (d, *J* = 8.0 Hz, 1H), 7.32 (d, *J* = 9.6 Hz, 4H), 7.27 (d, *J* = 8.0 Hz, 4H), 5.32 (d, *J* = 14.8 Hz, 1H), 4.76 (d, *J* = 13.2 Hz, 1H), 4.20 (d, *J* = 13.2 Hz, 1H), 4.05 (d, *J* = 14.8 Hz, 1H), 3.73 (s, 1H), 3.64-3.54 (m, 2H), 3.22 (s, 1H), 2.32 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 156.0, 148.0, 137.4, 136.4, 130.7, 130.5, 129.5, 129.0, 128.4, 128.3, 128.2, 125.6, 125.2, 59.1, 56.0, 48.2, 45.6, 20.1. HRMS (ESI) calcd for C₂₀H₂₁N₄O₂⁺(M+H)⁺ 349.1659, found 349.1650.

5-benzyl-6-(hydroxymethyl)-3-(m-tolyl)-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2k**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 63.2mg, 92%, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.97 (d, *J* = 8.8 Hz, 2H), 7.36-7.29 (m, 6H), 7.22 (d, *J* = 6.8 Hz, 1H), 5.44 (d, *J* = 16.0 Hz, 1H), 4.88 (d, *J* = 14.8 Hz, 1H), 4.22 (d, *J* = 13.2 Hz, 1H), 4.11 (d, *J* = 14.8 Hz, 1H), 3.79 (s, 1H), 3.67 (d, *J* = 11.2 Hz, 1H), 3.55 (t, *J* = 10.8 Hz, 1H), 3.47 (s, 1H), 2.41 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 156.3, 148.5, 138.1, 136.5, 130.3, 129.3, 129.1, 129.1, 128.8, 128.4, 128.2, 126.0, 123.8, 59.1, 56.0, 48.5, 45.8, 21.6. HRMS (ESI) calcd for C₂₀H₂₁N₄O₂⁺(M+H)⁺ 349.1659, found 349.1650.

5-benzyl-6-(hydroxymethyl)-3-(p-tolyl)-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2l**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 57.2 mg, 79%, white solid; ^1H NMR (400 MHz, CDCl_3) δ 8.09 (d, J = 7.6 Hz, 2H), 7.34 (t, J = 7.6 Hz, 5H), 7.27 (d, J = 7.2 Hz, 2H), 5.44 (d, J = 14.8 Hz, 1H), 4.90 (d, J = 14.0 Hz, 1H), 4.69 (s, 1H), 4.22 (dd, J = 13.6, 4.8 Hz, 1H), 4.14 (d, J = 14.8 Hz, 1H), 3.84-3.19 (m, 1H), 3.69 (dd, J = 11.2, 4.4 Hz, 1H), 3.58 (t, J = 10.4 Hz, 1H), 2.39 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 156.3, 148.5, 139.6, 136.5, 129.2, 129.1, 128.6, 128.3, 126.0, 123.6, 59.0, 56.0, 48.6, 45.7, 21.4. HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{21}\text{N}_4\text{O}_2^+(\text{M}+\text{H})^+$ 349.1659, found 349.1650.

5-benzyl-6-(hydroxymethyl)-3-(4-methoxyphenyl)-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2m**)



The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 59.3 mg, 82%, white solid; ^1H NMR (400 MHz, CDCl_3) δ 8.19 (d, J = 8.0 Hz, 2H), 7.38-7.31 (m, 5H), 6.98 (d, J = 8.0 Hz, 2H), 5.44 (d, J = 14.8 Hz, 1H), 4.91 (d, J = 13.6 Hz, 1H), 4.63 (s, 1H), 4.23 (dd, J = 13.6, 4.8 Hz, 1H), 4.15 (d, J = 14.8 Hz, 1H), 3.85 (s, 3H), 3.83-3.80 (m, 1H), 3.69 (dd, J = 11.6, 4.4 Hz, 1H), 3.57 (t, J = 10.4 Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 160.6, 156.4, 148.3, 136.5, 130.2, 129.1, 128.2, 128.2, 123.2, 121.4, 113.9, 59.0, 56.0, 55.4, 48.6, 45.6. HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{21}\text{N}_4\text{O}_3^+(\text{M}+\text{H})^+$ 365.1608, found 365.1598.


5-benzyl-3-(4-fluorophenyl)-6-(hydroxymethyl)-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2n**)



The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 68.6 mg, 98%, white solid; ^1H NMR (400 MHz, CDCl_3) δ 8.25 (t, J = 5.2 Hz, 2H), 7.38-7.31 (m, 5H), 7.14 (t, J = 8.4 Hz, 2H), 5.44 (d, J = 14.8 Hz, 1H), 4.93 (d, J = 13.6 Hz, 1H), 4.27 (dd, J = 13.2, 4.0 Hz 1H), 4.17 (d, J = 14.8 Hz, 1H), 3.87-3.82 (m, 1H), 3.70 (dd, J = 11.6, 4.8 Hz, 1H), 3.56 (t, J = 10.4 Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 163.5 (d, J = 124.0 Hz), 156.31, 147.59, 136.35, 130.8 (d, J = 9.0 Hz), 129.14, 128.34, 128.23, 125.1 (d, J = 3.0 Hz), 123.67, 115.5 (d, J = 21.0 Hz), 59.24, 55.89, 48.65,


45.76. HRMS (ESI) calcd for $C_{19}H_{18}FN_4O_2^+(M+H)^+$ 353.1408, found 353.1404.

5-benzyl-3-(4-chlorophenyl)-6-(hydroxymethyl)-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one
(2o)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 70.1 mg, 95%, white solid; 1H NMR (400 MHz, $CDCl_3$) δ 8.18 (d, J = 10.4 Hz, 2H), 7.43 (d, J = 9.2 Hz, 2H), 7.37-7.32 (m, 5H), 5.42 (dd, J = 14.8, 3.6 Hz, 1H), 4.91 (dd, J = 13.6, 3.2 Hz, 1H), 4.72 (q, J = 5.6 Hz, 1H), 4.26 (dt, J = 12.0, 4.0 Hz, 1H), 4.17 (dd, J = 14.8, 4.0 Hz, 1H), 3.86-3.81 (m, 1H), 3.70-3.66 (m, 1H), 3.57-3.50 (m, 1H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 156.2, 147.3, 136.3, 135.6, 130.0, 129.1, 128.7, 128.3, 128.2, 127.4, 124.0, 59.2, 56.0, 48.7, 45.8. HRMS (ESI) calcd for $C_{19}H_{18}ClN_4O_2^+(M+H)^+$ 369.1113, found 369.1104.

5-benzyl-3-(4-bromophenyl)-6-(hydroxymethyl)-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one
(2p)



The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 78.6 mg, 95%, white solid; 1H NMR (400 MHz, $CDCl_3$) δ 8.14 (d, J = 8.0 Hz, 2H), 7.59 (d, J = 8.0 Hz, 2H), 7.40-7.33 (m, 5H), 5.44 (d, J = 14.8 Hz, 1H), 4.93 (d, J = 13.6 Hz, 1H), 4.38 (s, 1H), 4.28 (dd, J = 14.0, 4.4 Hz, 1H), 4.18 (d, J = 14.8 Hz, 1H), 3.88-3.83 (m, 1H), 3.70 (d, J = 10.8 Hz, 1H), 3.54 (t, J = 10.4 Hz, 1H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 156.2, 147.4, 136.3, 131.7, 130.3, 129.1, 128.3, 128.2, 127.9, 124.0, 123.9, 59.2, 55.9, 48.7, 45.8. HRMS (ESI) calcd for $C_{19}H_{18}BrN_4O_2^+(M+H)^+$ 413.0608, found 413.0595.


5-benzyl-6-(hydroxymethyl)-3-(4-(trifluoromethyl)phenyl)-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one
(2q)



The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 79.2 mg, 98%, white solid; 1H NMR (400 MHz, $CDCl_3$) δ 8.44 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz,


2H), 7.43-7.31 (m, 5H), 5.47 (d, J = 14.8 Hz, 1H), 5.00 (d, J = 13.6 Hz, 1H), 4.36 (dd, J = 13.6, 4.4 Hz, 1H), 4.23 (d, J = 16.0 Hz, 1H), 3.93-3.88 (m, 1H), 3.74 (dd, J = 11.2, 4.4 Hz, 1H), 3.57 (t, J = 10.0 Hz, 1H), 1.97 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 156.1, 147.1, 136.2, 132.5, 131.1 (q, J = 32.0 Hz), 129.2, 129.0, 128.4, 128.3, 125.4 (q, J = 4.0 Hz), 124.56, 122.68, 59.54, 55.78, 48.74, 45.91. HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{18}\text{F}_3\text{N}_4\text{O}_2^+(\text{M}+\text{H})^+$ 403.1376, found 403.1363.

5-benzyl-3-(3,5-dichlorophenyl)-6-(hydroxymethyl)-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2r**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 76.4 mg, 95%, white solid; ^1H NMR (400 MHz, DMSO) δ 8.42 (d, J = 2.0 Hz, 2H), 7.66 (t, J = 2.0 Hz, 1H), 7.45-7.34 (m, 4H), 7.33-7.28 (m, 1H), 5.25 (d, J = 15.2 Hz, 1H), 5.19 (t, J = 5.2 Hz, 1H), 4.93 (d, J = 14.0 Hz, 1H), 4.70 (dd, J = 13.6, 5.2 Hz, 1H), 4.42 (d, J = 15.2 Hz, 1H), 3.93 (q, J = 4.8 Hz, 1H), 3.6-3.50 (m, 1H), 3.44-3.39 (m, 1H). ^{13}C NMR (100 MHz, DMSO) δ 156.56, 144.0, 137.6, 134.6, 133.6, 129.1, 128.6, 128.1, 127.9, 126.9, 125.7, 60.2, 56.6, 48.6, 46.5. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{17}\text{Cl}_2\text{N}_4\text{O}_2^+(\text{M}+\text{H})^+$ 403.0723, found 403.0713.

5-benzyl-6-(hydroxymethyl)-3-(thiophen-2-yl)-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2s**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 57.2 mg, 85%, white solid; ^1H NMR (400 MHz, CDCl_3) δ 8.30 (t, J = 3.6 Hz, 1H), 7.40 (t, J = 3.6 Hz, 1H), 7.36-7.32 (m, 5H), 7.12 (q, J = 4.0 Hz, 1H), 5.44 (dd, J = 15.2, 2.8 Hz, 1H), 4.94 (d, J = 13.2 Hz, 1H), 4.24 (dd, J = 14.0, 4.0 Hz, 1H), 4.18 (d, J = 14.4 Hz, 1H), 3.87-3.82 (m, 1H), 3.71 (dd, J = 11.6, 3.6 Hz, 1H), 3.57 (t, J = 10.4 Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 156.1, 143.6, 136.4, 130.8, 129.7, 129.1, 128.3, 128.3, 128.0, 127.7, 122.4, 59.0, 56.0, 48.5, 45.7. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{18}\text{BrNO}_2^+(\text{M}+\text{H})^+$ 341.1067, found 341.1059.

5-benzyl-6-(hydroxymethyl)-3-methyl-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2t**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 40.2 mg, 72%, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.32 (m, 5H), 5.43 (d, *J* = 14.8 Hz, 1H), 4.89 (d, *J* = 13.6 Hz, 1H), 4.21 (dt, *J* = 13.6, 4.0 Hz, 2H), 4.14 (d, *J* = 14.4 Hz), 3.86-3.80 (m, 1H), 3.72-3.67 (m, 1H), 3.54 (t, *J* = 10.4 Hz, 1H), 2.59 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 156.8, 145.9, 136.5, 129.1, 128.2, 128.2, 124.5, 58.8, 56.3, 48.0, 45.2, 11.0. HRMS (ESI) calcd for C₁₄H₁₇N₄O₂⁺(M+H)⁺ 273.1346, found 274.1336.

5-benzyl-6-(hydroxymethyl)-3-pentyl-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one (**2u**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 51.3 mg, 78%, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.41-7.34 (m, 5H), 5.43 (d, *J* = 14.8 Hz, 1H), 4.89 (d, *J* = 13.6 Hz, 1H), 4.21 (d, *J* = 11.2 Hz, 1H), 4.16 (d, *J* = 15.6 Hz, 1H), 3.84-3.80 (m, 1H), 3.70 (dd, *J* = 11.6, 4.4 Hz, 1H), 3.54 (t, *J* = 10.4 Hz, 1H), 3.00 (t, *J* = 8.0 Hz, 2H), 1.77 (q, *J* = 8.4 Hz, 2H), 1.39-1.35 (m, 4H), 0.91 (t, *J* = 6.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 156.6, 150.4, 136.5, 129.1, 128.3, 128.2, 124.2, 58.6, 56.3, 48.0, 45.1, 31.4, 28.6, 25.2, 22.4, 14.0. HRMS (ESI) calcd for C₁₈H₂₅N₄O₂⁺(M+H)⁺ 329.1972, found 329.1964.

N-benzyl-N-(oxetan-3-yl)-4-phenyl-1H-1,2,3-triazole-5-carboxamide(**2a'**)




The product was purified by silica gel column chromatography (dichloromethane/methanol = 200/1). 18.1mg, 27%, colorless oil, ¹H NMR (400 MHz, CDCl₃, two rotamers) δ 7.80-7.77 (m, 1H), 7.53-7.42 (m, 3H), 7.40-7.35 (m, 4H), 7.33-7.28 (m, 2H), 4.75 (d, *J* = 15.2 Hz, 1H), 4.54 (dd, *J* = 14.4, 4.0 Hz, 1H), 4.46-4.37 (m, 2H), 4.30 (d, *J* = 15.2 Hz, 1H), 4.28-4.20 (m, 2H). ¹³C NMR (100 MHz, CDCl₃, two rotamers) δ 158.1, 148.3, 135.6, 129.9, 129.2, 129.0, 128.6, 128.2, 125.8, 120.4, 65.2, 54.5, 50.7, 47.4. HRMS (ESI) calcd for C₁₉H₁₉N₄O₂⁺(M+H)⁺ 335.1503, found 335.1501.

General procedure for the synthesis of 6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-4(5H)-one




A mixture of **3** (0.2 mmol, 1.0 equiv), NaN_3 (0.2 mmol, 12.6 mg, 1.0 equiv), NaHCO_3 (0.2 mmol, 16.8 mg, 1.0 equiv) in DMSO (2 mL) was stirred at 120 °C for 12 hours . After the reaction was completed (monitored by TLC), H_2O (15.0 mL) and ethyl acetate (50.0 mL) were added. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (10.0 mL \times 3). The combined organic phase was washed with brine (10.0 mL \times 5) and further dried over Na_2SO_4 . The solvent was removed under reduced pressure and the residue was purified by flash chromatography (dichloromethane/methanol = 100/1) to afford the desired products **4**.

5-benzyl-7-(hydroxymethyl)-3-phenyl-5,6,7,8-tetrahydro-4H-[1,2,3]triazolo[1,5-a][1,4]diazepin-4-one (**4a**)



The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 55.3 mg, 80%, white solid; ^1H NMR (400 MHz, CDCl_3) δ 8.15 (d, J = 9.6 Hz, 2H), 7.49-7.42 (m, 2H), 7.39-7.38 (m, 6H), 5.14 (d, J = 14.4 Hz, 1H), 4.66 (d, J = 14.4 Hz, 1H), 4.54 (d, J = 14.8 Hz, 1H), 4.44-4.38 (m, 1H), 3.50-3.43 (m, 2H), 3.40-3.34 (m, 1H), 3.14-3.07 (m, 1H), 2.37-2.34(m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 161.2, 148.0, 136.7, 129.6, 129.1, 129.0, 128.6, 128.4, 128.3, 127.9, 127.8, 61.7, 51.0, 48.2, 47.1, 42.0. HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{21}\text{N}_4\text{O}_2^+(\text{M}+\text{H})^+$ 349.1659, found 349.1651.


5-benzyl-3-(4-fluorophenyl)-7-(hydroxymethyl)-5,6,7,8-tetrahydro-4H-[1,2,3]triazolo[1,5-a][1,4]diazepin-4-one (**4b**)



The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 65.2 mg, 90%, white solid; ^1H NMR (400 MHz, CDCl_3) δ 8.06 (d, J = 8.0 Hz, 2H), 7.59 (d, J = 8.0 Hz, 2H), 7.41-7.35 (m, 5H), 5.13 (d, J = 14.0 Hz, 1H), 4.65 (dd, J = 14.4, 3.6 Hz, 1H), 4.55 (d, J = 14.4 Hz, 1H), 4.43 (dd, J = 14.4, 6.8 Hz, 1H), 3.53-3.43 (m, 2H), 3.38 (dd, J = 15.2, 6.0 Hz, 1H), 3.13 (dd, J = 15.6, 9.2 Hz, 1H), 2.40-2.35 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 163.2 (d, J = 247.0 Hz), 161.16, 147.11, 136.61, 129.8 (d, J =8.0 Hz), 129.13, 128.40, 128.35, 127.73, 125.8 (d, J = 3.0 Hz), 115.63 (d, J = 21.0 Hz), 61.60, 51.04, 48.33, 47.18, 41.95. HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{20}\text{FN}_4\text{O}_2^+(\text{M}+\text{H})^+$ 367.1565,


found 367.1556.

5-benzyl-3-(4-chlorophenyl)-7-(hydroxymethyl)-5,6,7,8-tetrahydro-4H-[1,2,3]triazolo[1,5-a][1,4]diazepin-4-one (4c**)**




The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 66.2 mg, 87%, white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.11 (d, *J* = 8.0 Hz, 2H), 7.44-7.38 (m, 7H), 5.13 (d, *J* = 12.0 Hz, 1H), 4.65 (d, *J* = 12.0 Hz, 1H), 4.54 (d, *J* = 16.0 Hz, 1H), 4.41 (dd, *J* = 16.0, 8.0 Hz, 1H), 3.46 (s, 2H), 3.38 (dd, *J* = 16.0, 4.0 Hz, 1H), 3.11 (t, *J* = 12.0 Hz, 1H), 2.71 (s, 1H), 2.37 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 161.1, 146.9, 136.6, 135.0, 129.1, 128.9, 128.4, 128.1, 128.0, 61.6, 51.1, 48.3, 47.2, 41.9. HRMS (ESI) calcd for C₂₀H₂₀ClN₄O₂⁺(M+H)⁺ 383.1268, found 383.1259.

5-benzyl-3-(4-bromophenyl)-7-(hydroxymethyl)-5,6,7,8-tetrahydro-4H-[1,2,3]triazolo[1,5-a][1,4]diazepin-4-one (4d**)**



The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 69.2 mg, 81%, white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, *J* = 8.8 Hz, 2H), 7.60 (d, *J* = 7.6 Hz, 2H), 7.44-7.33 (m, 5H), 5.13 (d, *J* = 14.4 Hz, 1H), 4.65 (dd, *J* = 14.4, 3.6 Hz, 1H), 4.55 (d, *J* = 14.4 Hz, 1H), 4.43 (dd, *J* = 14.4, 6.8 Hz, 1H), 3.54-3.43 (m, 2H), 3.38 (dd, *J* = 14.4, 6.8 Hz, 1H), 3.13 (dd, *J* = 15.2, 9.2 Hz, 1H), 2.41-2.34 (m, 1H), 2.23-2.21 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 161.1, 147.0, 136.6, 131.8, 129.4, 129.2, 128.6, 128.4, 128.0, 123.3, 61.8, 51.1, 48.3, 47.1, 41.9. HRMS (ESI) calcd for C₂₀H₂₀BrN₄O₂⁺(M+H)⁺ 437.0764, found 437.0755.


5-benzyl-7-(hydroxymethyl)-3-(p-tolyl)-5,6,7,8-tetrahydro-4H-[1,2,3]triazolo[1,5-a][1,4]diazepin-4-one (4e**)**



The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 52.3 mg, 72%, white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, *J* = 8.0 Hz, 2H), 7.38-7.34 (m, 5H), 7.27 (s 1H), 7.25 (s, 1H), 5.11 (d, *J* = 14.4 Hz, 1H), 4.61 (dd, *J* = 14.4, 3.6 Hz, 1H), 4.52 (d, *J* = 14.4 Hz, 1H), 4.39 (dd, *J* = 12.0, 4.0 Hz, 1H), 3.50-3.40 (m, 2H), 3.34 (dd, *J* = 13.6, 6.4 Hz, 1H), 3.09 (dd, *J* = 12.0, 8.0 Hz, 1H), 2.39 (s, 3H), 2.36-2.30 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 161.3, 139.0, 136.8, 129.3, 129.1, 128.4, 128.3, 127.7, 127.6, 126.8, 61.7, 51.0, 48.2, 47.1, 41.9, 21.4. HRMS (ESI) calcd for


$C_{21}H_{23}N_4O_2^+(M+H)^+$ 363.1816, found 363.1807.

5-benzyl-3-(3,5-dimethylphenyl)-7-(hydroxymethyl)-5,6,7,8-tetrahydro-4H-[1,2,3]triazolo[1,5-a][1,4]diazepin-4-one (**4f**)



The product was purified by silica gel column chromatography (dichloromethane/methanol = 100/1). 55.3 mg, 76%, colourless oil; 1H NMR (400 MHz, $CDCl_3$) δ 7.71 (s, 2H), 7.43-7.32 (m, 5H), 7.05 (s, 1H), 5.11 (d, J = 15.6 Hz, 1H), 4.60 (dd, J = 14.4, 4.0 Hz, 1H), 4.55 (d, J = 14.4 Hz, 1H), 4.41 (dd, J = 16.0, 4.0 Hz, 1H), 3.50-3.43 (m, 2H), 3.35 (dd, J = 14.4, 6.8 Hz, 1H), 3.10 (dd, J = 15.6, 9.2 Hz, 1H), 2.89 (t, J = 4.4 Hz, 1H), 2.39 (s, 6H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 161.3, 148.2, 138.2, 136.8, 130.8, 129.3, 129.1, 128.4, 128.3, 127.8, 125.6, 61.6, 51.0, 48.2, 47.1, 42.0, 21.4. HRMS (ESI) calcd for $C_{22}H_{25}N_4O_2^+(M+H)^+$ 377.1972, found 377.1962.

IV. Synthetic Transformations



Gram synthesis of 2a: A mixture of **1a** (4 mmol, 1.16 g), NaN_3 (4 mmol, 252 mg), $NaHCO_3$ (4 mmol, 420 mg) in DMSO (10 mL) was stirred at 80 °C for 12 hours. After the reaction was completed (monitored by TLC), H_2O (15.0 mL) and ethyl acetate (50.0 mL) were added. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (10.0 mL \times 3). The combined organic phase was washed with brine, dried over Na_2SO_4 . The solvent was removed under reduced pressure and the residue was purified by flash chromatography (dichloromethane/methanol = 100/1) to afford the desired products **2a** in 91% yield. Notably, the

above resulting crude product was able to be recrystallized from petroleum ether and DCM to afford pure compound **4a** as white solid (74% yield).

Synthesis of 5: A mixture of **2a** (0.2 mmol, 66.8 mg) in TfOH (2 mL) was stirred at 120 °C for 12 hours. After the reaction was completed, the mixture was concentrated in vacuum and then loaded on silica column (ethyl acetate/petroleum ether = 2:1) to afford the title compound **5** in 67% yield. White solid; ¹H NMR (400 MHz, DMSO) δ 8.56 (d, *J* = 3.6 Hz, 1H), 8.30-8.27 (m, 2H), 7.49-7.39 (m, 3H), 5.17 (t, *J* = 5.6 Hz, 1H), 4.76-4.64 (m, 2H), 3.82-3.86 (m, 1H), 3.58-3.52 (m, 1H), 3.41-3.37 (m, 1H). ¹³C NMR (100 MHz, DMSO) δ 157.8, 146.8, 130.3, 129.3, 128.7, 128.7, 124.8, 61.6, 51.7, 46.7. HRMS (ESI) calcd for C₁₂H₁₃N₄O₂(M+H)⁺ 245.1033, found 245.1030.

Synthesis of 6: A mixture of **2a** (1.5 mmol, 501.0 mg), TsCl (1.5 mmol, 285.0 mg), Et₃N(2.25 mmol, 227.2 mg) in DCM (10 mL) was stirred at room temperature for 12 hours. After the reaction was completed, the mixture was concentrated in vacuum and then loaded on silica column (ethyl acetate/petroleum ether = 1:10) to afford the title compound **6** in 95% yield. White solid; ¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, *J* = 7.2 Hz, 2H), 7.59 (d, *J* = 7.2 Hz, 2H), 7.45 (q, *J* = 8.0 Hz, 3H), 7.39-7.31 (m, 5H), 7.23 (d, *J* = 8.0 Hz, 2H), 5.32 (d, *J* = 14.8 Hz, 1H), 4.80 (d, *J* = 14.0 Hz, 1H), 4.35 (dt, *J* = 14.0, 4.0 Hz, 1H), 4.24 (d, *J* = 14.8 Hz, 1H), 4.11-4.06 (m, 1H), 4.00-3.95 (m, 1H), 3.78 (t, *J* = 8.8 Hz, 1H), 2.36 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 156.2, 148.7, 145.8, 136.1, 131.6, 130.2, 129.4, 129.3, 129.2, 128.8, 128.4, 128.4, 127.7, 123.3, 65.6, 53.3, 48.7, 46.0, 21.7. HRMS (ESI) calcd for C₂₆H₂₅N₄O₄S^{+(M+H)} 489.1591, found 489.1578.

Synthesis of 7: A mixture of **6** (0.3 mmol, 146 mg), NaN₃ (0.3 mmol, 18.9 mg) in DMSO (2 mL) was stirred at 80 °C for 24 hours. After the reaction was complete (monitored by TLC), H₂O (15.0 mL) and ethyl acetate (50.0 mL) were added. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (10.0 mL × 3). The combined organic phase was washed with brine, dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue was purified by flash chromatography (ethyl acetate/petroleum ether = 1/5) to afford the desired products **7**. White solid; ¹H NMR (400 MHz, CDCl₃) δ 8.35 (d, *J* = 7.2 Hz, 2H), 7.52-7.41 (m, 3H), 7.40-7.34 (m, 5H), 5.40 (d, *J* = 14.8 Hz, 1H), 4.85 (d, *J* = 14.0 Hz, 1H), 4.37 (dd, *J* = 14.0, 4.8 Hz, 1H), 4.30 (d, *J* = 15.2 Hz, 1H), 3.86-3.81 (m, 1H), 3.43 (dd, *J* = 12.4, 5.2 Hz, 1H), 3.27 (dd, *J* = 12.8, 8.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 156.2, 149.0, 136.2, 129.5, 129.3, 129.2, 128.9, 128.5, 128.4, 128.3, 123.4, 53.8, 50.2, 48.7, 46.6. HRMS (ESI) calcd for C₁₉H₁₈N₇O^{+(M+H)} 360.1567, found 360.1558.

Synthesis of 8: A mixture of **6** (0.3 mmol, 146 mg), LiCl (0.3 mmol, 15.2 mg) in DMF (2 mL) was stirred at room temperature for 12 hours. After the reaction was complete (monitored by TLC), H₂O (15.0 mL) and ethyl acetate (50.0 mL) were added. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (10.0 mL × 3). The combined organic phase was washed with brine, dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue was purified by flash chromatography (ethyl acetate/petroleum ether = 1/5) to afford the desired products **8**. White solid; ¹H NMR (400 MHz, CDCl₃) δ 8.35 (d, *J* = 8.0 Hz, 2H), 7.51-7.44 (m, 3H), 7.40-7.35 (m, 5H), 5.39 (d, *J* = 14.8 Hz, 1H), 5.11 (d, *J* = 14.0 Hz, 1H), 4.41-4.36 (m, 1H), 4.29 (d, *J* = 14.8 Hz, 1H), 3.97 (q, *J* = 5.2 Hz, 1H), 3.50 (d, *J* = 10.4 Hz, 1H), 3.28 (t, *J* = 11.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 156.0, 149.0, 136.1, 129.5, 129.3, 129.2, 128.9, 128.5, 128.4, 128.3, 123.3, 56.1, 48.6, 46.1, 40.6. HRMS (ESI) calcd

for C₁₉H₁₈ClN₄O⁺(M+H)⁺ 353.1164, found 353.1155.


V. X-Ray Crystallographic Data 2a

X-Ray Crystallographic Data of 2a

Compounds **2a** were collected at 100 K on a Rigaku Oxford Diffraction Supernova Dual Source, Cu at Zero equipped with an AtlasS2 CCD using Cu K α radiation. The data were collected and processed using CrysAlisPro22.

Compound **2a** was completely dissolved in ethyl acetate (0.3 mL). Hexanes (1.0 mL) was added slowly to the solution at room temperature. The solvent diffused slowly, and the single crystal was obtained after two days. The structure in Figure S1 showed the absolute configuration of **2a**. The CCDC number is 2386562. These details can be obtained free of charge via www.ccdc.com.ac.uk/data_request/cif from the Cambridge Crystallographic Data Centre.

Figure S1. Thermal Ellipsoid Plot for 2a (50% probability level)




Crystal Data for 2a

Table 1 Crystal data and structure refinement for FC-B149T.

Identification code	FC-B149T
Empirical formula	C ₁₉ H ₁₈ N ₄ O ₂
Formula weight	334.37
Temperature/K	177(12)
Crystal system	triclinic
Space group	P-1
a/Å	8.9365(3)


b/Å	9.5864(4)
c/Å	21.4457(8)
$\alpha/^\circ$	82.342(3)
$\beta/^\circ$	85.179(3)
$\gamma/^\circ$	65.019(4)
Volume/Å ³	1649.71(12)
Z	4
$\rho_{\text{calc}}/\text{cm}^3$	1.346
μ/mm^{-1}	0.732
F(000)	704.0
Crystal size/mm ³	0.15 × 0.13 × 0.12
Radiation	Cu Kα ($\lambda = 1.54184$)
2Θ range for data collection/°	4.16 to 148.054
Index ranges	-11 ≤ h ≤ 8, -11 ≤ k ≤ 10, -25 ≤ l ≤ 26
Reflections collected	11372
Independent reflections	6464 [$R_{\text{int}} = 0.0376$, $R_{\text{sigma}} = 0.0464$]
Data/restraints/parameters	6464/0/453
Goodness-of-fit on F^2	1.026
Final R indexes [I>=2σ (I)]	$R_1 = 0.0507$, $wR_2 = 0.1362$
Final R indexes [all data]	$R_1 = 0.0565$, $wR_2 = 0.1454$
Largest diff. peak/hole / e Å ⁻³	0.30/-0.26




1a

^1H NMR

400MHz CDCl_3








1a

¹³C NMR

100MHz CDCl₃









1b
 ^{13}C NMR


100MHz CDCl_3






¹H NMR

400MHz CDCl₃





1c
 ^{13}C NMR
100 MHz CDCl₃

~154.90
~154.40

132.39
132.37
130.32
130.23
128.63
120.34
120.15


90.93
~90.06
81.90
81.53
76.20
~75.38


52.31
51.85
~50.27
~47.62
35.67
~35.20
26.86
~26.22
~18.29
~18.22

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10

f1 (ppm)


700
650
600
550
500
450
400
350
300
250
200
150
100
50
0
-50







1d
¹³C NMR

100MHz CDCl₃










^{13}C NMR


100MHz CDCl_3






1f
¹H NMR
400MHz CDCl₃







1f

^{13}C NMR
100MHz CDCl_3







1g

^{13}C NMR

100MHz CDCl_3


-154.87


138.74
~137.72
~132.50
~132.49
130.40
130.35
128.95
128.91
128.77
128.75
128.66
127.04
126.75
120.21
120.10

90.90
~89.99
81.73
~81.34
76.05
~75.48

-52.82
~50.04
~48.24
~44.74

~37.08
~34.64
~29.71







1h

^1H NMR

400MHz CDCl_3







1h

^{13}C NMR


100MHz CDCl_3






¹H NMR

400MHz CDCl₃





0.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 -1.0


*f*₁ (ppm)





¹³C NMR
100MHz CDCl₃
















11

^1H NMR


400MHz CDCl_3







11
 ^{13}C NMR


100MHz CDCl_3






1m
 ^1H NMR
400MHz CDCl_3









1m

^{13}C NMR
100MHz CDCl_3











¹H NMR


400MHz CDCl₃




1.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5


f1 (ppm)










1 p


 ^{13}C NMR100MHz CDCl₃









1q
 ^{13}C NMR
100MHz CDCl_3











1s
 ^{13}C NMR

100MHz CDCl_3

— 155.16

137.08
136.67
135.69
135.62
130.72
130.56
129.10
128.88
127.97
127.63
127.53
127.46
126.75
126.56
119.73


— 85.75

75.77
75.34


52.64
50.24
49.86
— 45.51


180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -100

f1 (ppm)





1t
 ^1H NMR
400MHz CDCl_3






1t
 ^{13}C NMR
100MHz CDCl_3







1u
 ^1H NMR

400MHz CDCl_3










^1H NMR


400MHz CDCl_3










¹H NMR
400MHz CDCl₃









^1H NMR

400MHz CDCl_3



10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 -0.5 -1.0

f1 (ppm)




¹³C NMR


100MHz CDCl₃


—158.05
—148.34
—120.40


135.56
129.90
129.22
128.94
128.55
128.21
125.79


—65.17
—54.47
—50.73
—47.38













¹³C NMR
100MHz CDCl₃


156.18
148.06
129.43
128.71
128.44
124.10
58.96
57.32
50.77
45.41
34.31
26.31
26.10
18.42






¹H NMR


400 MHz CDCl₃









2d
¹³C NMR


100MHz CDCl₃


















¹H NMR

400MHz CDCl₃









2h

 ^{13}C NMR100MHz CDCl_3

137.61
129.41
129.05
128.70
128.57
128.42
128.02
127.79
124.02

—156.37
—148.11


—73.51
—68.70
—59.68
—58.69

—46.66
—45.58

210 200 190 180 170 160 150 140 130 120 110 100 80 70 60 50 40 30 20 10 0 -10


f1 (ppm)


4000
3800
3600
3400
3200
3000
2800
2600
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
-200
-400





^1H NMR


400MHz CDCl_3















2l
 ^1H NMR


400MHz CDCl_3






















¹H NMR


400MHz CDCl₃




























¹H NMR

400MHz CDCl₃










¹H NMR

400MHz CDCl₃









2u
¹H NMR


400MHz CDCl₃







2u
¹³C NMR

100MHz CDCl₃









3a

^{13}C NMR


100MHz CDCl_3






3b
 ^1H NMR

400MHz CDCl_3








3b

^{13}C NMR

100MHz CDCl_3











3c
 ^{13}C NMR


100MHz CDCl_3






















































^1H NMR

400MHz DMSO





^{13}C NMR

100MHz DMSO

